Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00076024 · ClinicalTrials.gov registry record · Phase 1

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

A Phase 1 study of Breast Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
174
Enrollment target
20
Study locations

NCT00076024 is a Phase 1 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 174 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00076024, a Phase 1 study of Breast Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
174 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.

Conditions Studied

Breast Neoplasms

Interventions

  • DRUG Placebo
  • DRUG Docetaxel
  • DRUG AG-013736 (axitinib)

Study Locations (20)

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville Beach
  • Pfizer Investigational Site - Melbourne
  • Pfizer Investigational Site - Orange Park
  • Pfizer Investigational Site - Palatka
  • Pfizer Investigational Site - Saint Augustine

California

  • Pfizer Investigational Site - Berkeley
  • Pfizer Investigational Site - Montebello
  • Pfizer Investigational Site - Monterey Park
  • Pfizer Investigational Site - San Francisco
  • Pfizer Investigational Site - San Gabriel
  • Pfizer Investigational Site - Whittier

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Zion

Arizona

  • Pfizer Investigational Site - Tucson
  • Pfizer Investigational Site - Tucson

Massachusetts

  • Pfizer Investigational Site - Boston

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2004-02
Est. Completion 2008-11
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00076024

The ClinicalTrials.gov registry entry for NCT00076024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (69% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00076024 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00076024 about?

NCT00076024 is a clinical study titled "AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer". The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of...

What is the current status of trial NCT00076024?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2004-02. Estimated completion is 2008-11.

What conditions does trial NCT00076024 study?

This clinical trial studies the following conditions: Breast Neoplasms.

What interventions are being tested in trial NCT00076024?

The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), AG-013736 (axitinib) (DRUG).

Who is sponsoring clinical trial NCT00076024?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00076024 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.